Beste Lydia01,
Ik zag je verhaal over stollingsproblemen. Nou weet ik dat er onderzoek is geweest naar het slikken van aspirine (100mg) bij stollingsproblemen of 3 of meer miskramen. De resultaten zijn best wel posititief bij stollingsproblemen. Aspirine verdunt namelijk het bloed (let op, paracetamol doet niet hetzelfde). Door de lichte bloedverdunning gaat de innesteling beter, vooral het aanleggen van de eerste bloedbaantjes van de placenta met de moeder.
Hieronder wat studies. Iets om met je arts te bespreken. Let op bij het lezen van dit soort studies: er is altijd veel voorbehoud en de oorzaak van de herhalende miskramen kunnen verschillend zijn, waardoor resultaten van behandeling ook verschillend zijn.
Ik heb geprobeerd studies toe te voegen die zoveel mogelijk het hebben over stollingsproblematiek... Ik weet dat er een jaar of 4-5 geleden in Nederland zelfs een onderzoek heeft gelopen. Hierbij werden vrouwen die 3 of meer miskramen hadden gehad op 100mg aspirine gezet. Resultaten waren positief, maar toen nog niet gepubliceerd. Misschien kan je arts wel aan de publicaties komen...
Succes!
Nicky
Recurrent miscarriage: causes, evaluation, and treatment.
Bick RL, Madden J, Heller KB, Toofanian A.
Thrombosis Clinical Center, Department of Medicine (Hematology & Oncology), Presbyterian Hospital of Dallas, Tex., USA.
Recurrent miscarriage or fetal loss syndrome (also known as fetal wastage syndrome) is characterized by recurrent spontaneous abortion. There are many syndromes associated with recurrent fetal loss, including anatomic anomalies, endocrine/hormonal abnormalities, genetic/chromosomal abnormalities, and blood coagulation protein/platelet defects. Many of these syndromes are treatable, leading to normal term pregnancy, if the clinician is astute and vigorously pursues a thorough evaluation of why the patient has suffered unexplained, spontaneous miscarriages. There is no uniform agreement on how many spontaneous, unexplained miscarriages are needed to diagnose recurrent fetal loss; we generally pursue an evaluation for causation if a women has had 2 or more such events. In this article, we discuss the common reasons for recurrent fetal loss, plus diagnostic procedures to consider in pinpointing the problem, such as cytogenetic studies, blood coagulation protein/platelet tests, hysterosalpingography, sonography, and magnetic resonance imaging. We also describe management strategies that often lead to successful pregnancy outcome when the underlying problem is addressed. For example, in the case of thrombotic defects, a common cause of recurrent fetal loss, we report a 100% success rate in achieving a normal-term delivery among women who took low-dose (81 mg/day) aspirin preconception followed by postconception low-dose (5000 units q 12 h) heparin.
Ruopp MD, Collins TC, Whitcomb BW, Schisterman EF.
Division of Epidemiology, Statistics and Prevention Research, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
OBJECTIVE: To assess the conflicting evidence whether low-dose aspirin is beneficial in IVF and to evaluate the meta-analysis performed by Gelbaya et al. and reported in March 2007 in Human Reproduction Update, in which they found no effects of low-dose aspirin and recommended discontinuing its use in IVF. We present a reanalysis of the effects of low-dose aspirin in IVF and raise methodological questions regarding the analysis by Gelbaya et al. DESIGN: A meta-analysis of prospective randomized trials evaluating the effects of low-dose aspirin in IVF. PATIENT(S): Women undergoing IVF/intracytoplasmic sperm injection. INTERVENTION(S): Low-dose acetylsalicylic acid (aspirin). MAIN OUTCOME MEASURE(S): Pregnancy rates, implantation rates, miscarriage rates. RESULT(S): Ten randomized clinical trials were included in the analysis. Clinical pregnancy rate per ET was significant when low-dose aspirin was compared with no treatment (risk ratio 1.15, 95% confidence interval 1.03-1.27). Nonsignificant estimates comparing low-dose aspirin with no treatment were found for implantation and miscarriage rates. CONCLUSION(S): Our results suggest that aspirin may increase clinical pregnancy rates and that more data are needed to resolve the issue. At this point, there is no reason to change clinical management and discontinue the use of aspirin.
Ik zag je verhaal over stollingsproblemen. Nou weet ik dat er onderzoek is geweest naar het slikken van aspirine (100mg) bij stollingsproblemen of 3 of meer miskramen. De resultaten zijn best wel posititief bij stollingsproblemen. Aspirine verdunt namelijk het bloed (let op, paracetamol doet niet hetzelfde). Door de lichte bloedverdunning gaat de innesteling beter, vooral het aanleggen van de eerste bloedbaantjes van de placenta met de moeder.
Hieronder wat studies. Iets om met je arts te bespreken. Let op bij het lezen van dit soort studies: er is altijd veel voorbehoud en de oorzaak van de herhalende miskramen kunnen verschillend zijn, waardoor resultaten van behandeling ook verschillend zijn.
Ik heb geprobeerd studies toe te voegen die zoveel mogelijk het hebben over stollingsproblematiek... Ik weet dat er een jaar of 4-5 geleden in Nederland zelfs een onderzoek heeft gelopen. Hierbij werden vrouwen die 3 of meer miskramen hadden gehad op 100mg aspirine gezet. Resultaten waren positief, maar toen nog niet gepubliceerd. Misschien kan je arts wel aan de publicaties komen...
Succes!
Nicky
Recurrent miscarriage: causes, evaluation, and treatment.
Bick RL, Madden J, Heller KB, Toofanian A.
Thrombosis Clinical Center, Department of Medicine (Hematology & Oncology), Presbyterian Hospital of Dallas, Tex., USA.
Recurrent miscarriage or fetal loss syndrome (also known as fetal wastage syndrome) is characterized by recurrent spontaneous abortion. There are many syndromes associated with recurrent fetal loss, including anatomic anomalies, endocrine/hormonal abnormalities, genetic/chromosomal abnormalities, and blood coagulation protein/platelet defects. Many of these syndromes are treatable, leading to normal term pregnancy, if the clinician is astute and vigorously pursues a thorough evaluation of why the patient has suffered unexplained, spontaneous miscarriages. There is no uniform agreement on how many spontaneous, unexplained miscarriages are needed to diagnose recurrent fetal loss; we generally pursue an evaluation for causation if a women has had 2 or more such events. In this article, we discuss the common reasons for recurrent fetal loss, plus diagnostic procedures to consider in pinpointing the problem, such as cytogenetic studies, blood coagulation protein/platelet tests, hysterosalpingography, sonography, and magnetic resonance imaging. We also describe management strategies that often lead to successful pregnancy outcome when the underlying problem is addressed. For example, in the case of thrombotic defects, a common cause of recurrent fetal loss, we report a 100% success rate in achieving a normal-term delivery among women who took low-dose (81 mg/day) aspirin preconception followed by postconception low-dose (5000 units q 12 h) heparin.
Ruopp MD, Collins TC, Whitcomb BW, Schisterman EF.
Division of Epidemiology, Statistics and Prevention Research, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
OBJECTIVE: To assess the conflicting evidence whether low-dose aspirin is beneficial in IVF and to evaluate the meta-analysis performed by Gelbaya et al. and reported in March 2007 in Human Reproduction Update, in which they found no effects of low-dose aspirin and recommended discontinuing its use in IVF. We present a reanalysis of the effects of low-dose aspirin in IVF and raise methodological questions regarding the analysis by Gelbaya et al. DESIGN: A meta-analysis of prospective randomized trials evaluating the effects of low-dose aspirin in IVF. PATIENT(S): Women undergoing IVF/intracytoplasmic sperm injection. INTERVENTION(S): Low-dose acetylsalicylic acid (aspirin). MAIN OUTCOME MEASURE(S): Pregnancy rates, implantation rates, miscarriage rates. RESULT(S): Ten randomized clinical trials were included in the analysis. Clinical pregnancy rate per ET was significant when low-dose aspirin was compared with no treatment (risk ratio 1.15, 95% confidence interval 1.03-1.27). Nonsignificant estimates comparing low-dose aspirin with no treatment were found for implantation and miscarriage rates. CONCLUSION(S): Our results suggest that aspirin may increase clinical pregnancy rates and that more data are needed to resolve the issue. At this point, there is no reason to change clinical management and discontinue the use of aspirin.